HALOHalozyme Therapeutics, Inc.

$110.41+42% 1Y

$110.41

$61.6352 weeks$115.27

HALO in its own filings

HALO's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.

450

Events found in the filings · across 1,516 filings · the record starts in 2002

Hard flags: 2
Hard flags
Most recent filing: Sep 30, 2026
Most recent filing · Form 8-K
Record starts: Aug 14, 2002
Record starts · the earliest filing Ryufin holds for this name

Details›

Next results filingsame week as a year ago: expected around Nov 2, 2026
Change in certifying accountanthistorical: 2006-06-29
Late periodic report2 occurrences: 2003-05-16
Delisting notice / listing-rule failurehistorical: 2007-11-20
Security removed from listing or deregisteredhistorical · usually a matured note or preferred class, not the common shares: 2007-05-09
Material impairment2 occurrences: 2019-11-12
SEC comment-letter activity30 occurrences: 2023-07-21

SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.

What the company said

The company's own words from its current reports to the SEC, newest first

Sep 30, 2026On September 28, 2026, James Daly was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Mr. Daly was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2029 and was not initially assigned to any Board committee.Director or officer change · Form 8-K
Sep 22, 2026Convertible Notes Indentures On September 22, 2026, Halozyme Therapeutics, Inc. (the “Company,” “we,” “us” or “our”) completed its previously announced sale of $1,500.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2033 (the “Convertible Notes”), including $200.0 million in aggregate …Material agreement entered · Form 8-K
Sep 18, 2026On September 17, 2026, Halozyme Therapeutics, Inc. (the “Company”) issued a press release announcing the pricing of its offering of $1.3 billion aggregate principal amount of convertible senior notes due 2033 (the “Convertible Notes”)Other event · Form 8-K
Sep 16, 2026On September 16, 2026, Halozyme Therapeutics, Inc. (the “Company”) issued a press release announcing that it proposes to offer, subject to market conditions and other factors, $1.05 billion aggregate principal amount of convertible senior notes due 2033 (the “Convertible Notes”)Other event · Form 8-K
Aug 18, 2026On August 14, 2026, Dannielle Appelhans was elected to the Board of Directors of Halozyme Therapeutics, Inc. (the “Company”). Ms. Appelhans was elected to the class of directors with terms ending at the Company’s annual meeting of stockholders in 2028 and was not initially assigned to any Board committee.Director or officer change · Form 8-K
Aug 6, 2026Total Revenue Increased 48% YOY to $481 million.Earnings release · press release
Jul 2, 2026On June 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced an update to its senior management structure. The company also announced the departure of Cortney Caudill as the Company’s Senior Vice President, Chief Operating Officer.Director or officer change · Form 8-K
May 11, 2026Announcing New $1 billion Share Repurchase Program.Earnings release · press release
Apr 30, 2026On April 30, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that Darren Snellgrove has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), effective June 8, 2026.Director or officer change · Form 8-K
Apr 24, 2026On April 22, 2026, the Board of Directors (the “Board”) of Halozyme Therapeutics, Inc. (the “Company”) amended the Company’s Bylaws to revise (i) Section 2.5 to provide that directors may be removed from office at any time, with or without cause, by the holders of a majority of the shares then entitled to vote at an …Charter/bylaw amendment or fiscal-year change · Form 8-K
Mar 12, 2026On March 12, 2026, Halozyme Therapeutics, Inc. (the “Company”) announced that David Ramsay has been appointed to serve as the Company’s Interim Chief Financial Officer (“Interim CFO”), effective March 23, 2026.Director or officer change · Form 8-K